Immunotec names new executive vice president and COO
Mr Murphy, formerly vice president of finance and CFO at Princess House will report directly to James Northrop, president and CEO of Immunotec. Prior to joining Immunotec, Mr
Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab) to treat multiple sclerosis (MS).